IP21-002 Enhanced Surveillance for New Vaccine Preventable Diseases
IP21-002 加强对新疫苗可预防疾病的监测
基本信息
- 批准号:10669094
- 负责人:
- 金额:$ 275万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-01 至 2026-08-31
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
PROJECT SUMMARY - Mandatory Component A
Acute respiratory illness (ARI) and acute gastroenteritis (AGE) are the leading causes of death worldwide in
young children. Established leading viral etiologies of AGE are rotavirus and norovirus and respiratory syncytial
virus (RSV) and influenza virus for ARI. Our understanding of ARI and AGE epidemiology is constantly
changing due to spatiotemporal fluctuations, discovery of new or re-emerging pathogens [e.g. enterovirus D68
(EV-D68) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)], and use of rotavirus and
influenza vaccines. Hence, surveillance efforts are imperative to define ARI and AGE disease burden,
causative pathogens, outcomes, and vaccine impact. The primary influenza prevention strategy in the United
States is vaccination for all individuals six months or older. There is a paucity of data regarding vaccine
effectiveness (VE) against laboratory-confirmed influenza in children, and influenza viruses and vaccine
antigenic components change annually. Therefore, perpetual assessments of VE are needed to monitor the
impact of influenza vaccination on disease and inform strategies to improve magnitude, durability, and breadth
of protection. Pediatric SARS-CoV-2 vaccines are an urgent public-health priority and likely will become
available on an accelerated timeline in an effort to curb the COVID-19 pandemic. Rigorous, prospective
surveillance of SARS-CoV-2 VE is crucial to support reliance on vaccines as primary prevention. Thus, the
first main objective of this project is to conduct population-based active surveillance for respiratory and
enteric viral pathogens in pediatric inpatient and emergency department settings and asymptomatic
controls. Our team of Vanderbilt investigators is highly experienced in conducting prospective, population-
based ARI and AGE surveillance. We propose to conduct ARI and AGE surveillance with the following specific
aims: 1) To perform prospective, active surveillance to determine the etiology and burden of inpatient and
emergency department (ED) acute viral respiratory and enteric diseases among the pediatric population. 2) To
characterize the clinical and epidemiologic factors of pediatric infections (including in asymptomatic children)
through active surveillance. 3) To evaluate vaccine effectiveness and impact of vaccines and other
interventions (e.g., immunoprophylaxis with antiviral agents or other therapeutics) available or projected to
become available during the period of performance. The second main objective of this project is to conduct
surveillance and epidemiologic characterization of acute flaccid myelitis syndrome in children. Given
the epidemiologic connection between EV-D68 infection and acute flaccid myelitis (AFM), it will be important to
conduct rigorous, active, longitudinal surveillance for AFM across multiple consecutive seasons; carefully
define AFM clinical spectrum, risk factors, incidence rates, and laboratory parameters; and document local
circulation of EV-D68 and other ARI and AGE pathogens coincident with increased AFM occurrence. This work
underpins development of preventive, diagnostic, and therapeutic strategies for AFM.
项目摘要-必修组成部分A
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NATASHA Bassam HALASA其他文献
NATASHA Bassam HALASA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NATASHA Bassam HALASA', 18)}}的其他基金
Comparison of High Dose vs. Standard Dose Influenza Vaccines in Lung Allograft Recipients
同种异体肺移植受者中高剂量与标准剂量流感疫苗的比较
- 批准号:
10576411 - 财政年份:2022
- 资助金额:
$ 275万 - 项目类别:
Comparison of High Dose vs. Standard Dose Influenza Vaccines in Lung Allograft Recipients
同种异体肺移植受者中高剂量与标准剂量流感疫苗的比较
- 批准号:
10405753 - 财政年份:2022
- 资助金额:
$ 275万 - 项目类别:
Enhanced Surveillance for New Vaccine Preventable Diseases
加强对新疫苗可预防疾病的监测
- 批准号:
10345655 - 财政年份:2021
- 资助金额:
$ 275万 - 项目类别:
Enhanced Surveillance for New Vaccine Preventable Diseases
加强对新疫苗可预防疾病的监测
- 批准号:
10469296 - 财政年份:2021
- 资助金额:
$ 275万 - 项目类别:
Comparison of High vs. Standard Dose Influenza Vaccines in Adult Solid Organ Transplant Recipients
成人实体器官移植受者中高剂量与标准剂量流感疫苗的比较
- 批准号:
10447747 - 财政年份:2020
- 资助金额:
$ 275万 - 项目类别:
Comparison of High vs. Standard Dose Influenza Vaccines in Adult Solid Organ Transplant Recipients
成人实体器官移植受者中高剂量与标准剂量流感疫苗的比较
- 批准号:
10246980 - 财政年份:2020
- 资助金额:
$ 275万 - 项目类别:
Comparison of High vs. Standard Dose Influenza Vaccines in Adult Solid Organ Transplant Recipients
成人实体器官移植受者中高剂量与标准剂量流感疫苗的比较
- 批准号:
10661582 - 财政年份:2020
- 资助金额:
$ 275万 - 项目类别:
Comparison of High vs. Standard Dose Influenza Vaccines in Adult Solid Organ Transplant Recipients
成人实体器官移植受者中高剂量与标准剂量流感疫苗的比较
- 批准号:
10017602 - 财政年份:2020
- 资助金额:
$ 275万 - 项目类别:
High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients
成人干细胞移植受者的高剂量流感疫苗与标准剂量流感疫苗
- 批准号:
9352550 - 财政年份:2017
- 资助金额:
$ 275万 - 项目类别:
Comparison of High vs. Standard Dose Flu Vaccine in Pediatric Stem Cell Transplant Recipients
儿童干细胞移植受者中高剂量流感疫苗与标准剂量流感疫苗的比较
- 批准号:
9144608 - 财政年份:2016
- 资助金额:
$ 275万 - 项目类别:
相似国自然基金
锌粉(002)晶面定向调控及其负极性能强化机理研究
- 批准号:2025JJ70625
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
新型核素偶联药载体JBN002-DOTA的开发及其在肿瘤诊疗中的应用
- 批准号:82373174
- 批准年份:2023
- 资助金额:60 万元
- 项目类别:面上项目
tiRNA-Val-CAC-002介导ITGB3/PI3K/Akt调控FB自噬促进OSF发生机制研究
- 批准号:2023JJ30946
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
双胍新衍生物SMK-002阻断PKM2入核下调脂质合成抑制EMT阻止膀胱癌转移的作用和机制研究
- 批准号:
- 批准年份:2021
- 资助金额:55 万元
- 项目类别:面上项目
tiRNA-Gly-GCC-002 调控FKBP5 在狼疮性肾炎肾小管上皮细胞损伤中的作用及机制研究
- 批准号:LY22H050004
- 批准年份:2021
- 资助金额:0.0 万元
- 项目类别:省市级项目
关键挥发性有机物介导根际促生菌NRCB002定殖的根际生物学机制
- 批准号:32172673
- 批准年份:2021
- 资助金额:58 万元
- 项目类别:面上项目
外泌体lncRNAuc002ktr.3在肺鳞癌顺铂耐药中的作用及其作为新型耐药标志物的临床价值
- 批准号:81972006
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
宿主LncRNAs LNC_002与Linc00152调控肠道病原菌感染炎症反应的分子机制研究
- 批准号:81902027
- 批准年份:2019
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
RELA/ LncRNA-uc002jit.1/PARP1形成环路调节DNA修复对DNA损伤药物清除白血病干细胞的影响
- 批准号:81872898
- 批准年份:2018
- 资助金额:57.0 万元
- 项目类别:面上项目
基因间长非编码RNA-UC002yug.2调控成骨细胞功能及其在绝经后骨质疏松症中的作用机制
- 批准号:81760595
- 批准年份:2017
- 资助金额:40.0 万元
- 项目类别:地区科学基金项目
相似海外基金
IP21-002, Enhanced Surveillance to Assess Vaccine Preventable Enteric and Respiratory Virus Illnesses
IP21-002,加强监测以评估疫苗可预防的肠道和呼吸道病毒疾病
- 批准号:
10472389 - 财政年份:2021
- 资助金额:
$ 275万 - 项目类别:
IP21-002, Enhanced Surveillance to Assess Vaccine Preventable Enteric and Respiratory Virus Illnesses
IP21-002,加强监测以评估疫苗可预防的肠道和呼吸道病毒疾病
- 批准号:
10674580 - 财政年份:2021
- 资助金额:
$ 275万 - 项目类别:
IP21-002 US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children
IP21-002 美国增强监测网络,评估预防儿童肠道和呼吸道病毒的疫苗负担、自然史和有效性
- 批准号:
10669091 - 财政年份:2021
- 资助金额:
$ 275万 - 项目类别:
IP21-002, Enhanced Surveillance Network for Enteric and Respiratory Viruses in Children: Assessing Disease Burden, Natural History, and Vaccine Effectiveness
IP21-002,儿童肠道和呼吸道病毒的增强监测网络:评估疾病负担、自然史和疫苗有效性
- 批准号:
10340747 - 财政年份:2021
- 资助金额:
$ 275万 - 项目类别:
IP21-002, Enhanced Surveillance Network for Enteric and Respiratory Viruses in Children: Assessing Disease Burden, Natural History, and Vaccine Effectiveness
IP21-002,儿童肠道和呼吸道病毒的增强监测网络:评估疾病负担、自然史和疫苗有效性
- 批准号:
10674572 - 财政年份:2021
- 资助金额:
$ 275万 - 项目类别:
IP21-002, Enhanced Surveillance Network for Enteric and Respiratory Viruses in Children: Assessing Disease Burden, Natural History, and Vaccine Effectiveness
IP21-002,儿童肠道和呼吸道病毒的增强监测网络:评估疾病负担、自然史和疫苗有效性
- 批准号:
10469295 - 财政年份:2021
- 资助金额:
$ 275万 - 项目类别:
IP21-002, Enhanced Surveillance to Assess Vaccine Preventable Enteric and Respiratory Virus Illnesses
IP21-002,加强监测以评估疫苗可预防的肠道和呼吸道病毒疾病
- 批准号:
10343251 - 财政年份:2021
- 资助金额:
$ 275万 - 项目类别:
IP21-002, US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children
IP21-002,美国增强监测网络,评估预防儿童肠道和呼吸道病毒的疫苗负担、自然史和有效性
- 批准号:
10472401 - 财政年份:2021
- 资助金额:
$ 275万 - 项目类别:
IP21-002, US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children
IP21-002,美国增强监测网络,评估预防儿童肠道和呼吸道病毒的疫苗负担、自然史和有效性
- 批准号:
10674575 - 财政年份:2021
- 资助金额:
$ 275万 - 项目类别:
IP21-002, US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children
IP21-002,美国增强监测网络,评估预防儿童肠道和呼吸道病毒的疫苗负担、自然史和有效性
- 批准号:
10347783 - 财政年份:2021
- 资助金额:
$ 275万 - 项目类别: